On 12 July 2013, Afatinib was approved by the FDA for use in the treatment of patients with metastatic NSCLC with a mutation in the EGFR (EGFR exon 19 deletions or exon 21 (L858R) substitution mutations) [36]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.